ITM Isotope Technologies Munich SE to Present at ESMO 2025
ITM Isotope Technologies Munich SE (ITM), known for its leading role in the radiopharmaceutical field, has exciting news for healthcare professionals and cancer researchers alike. The company is preparing to showcase new data on the efficacy and safety of their investigational treatment, which emerged from the innovative Phase 3 COMPETE trial. This important data will be revealed in an oral presentation at the upcoming European Society for Medical Oncology (ESMO) Congress.
Details of the Oral Presentation
The highly anticipated oral presentation will take place on a notable day, presented by the esteemed study investigator, Dr. Jaume Capdevila, MD, PhD. Dr. Capdevila's presentation is titled, “Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial.” This enlightening talk is set for Saturday in the NETs and Endocrine Tumors Proffered Paper Session, making it a cornerstone event for participants at ESMO.
Presentation Insights
Similar studies have set the stage for expectations regarding the outcomes of this trial. Previous research suggested significant advancements and potential breakthroughs in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and attendees can anticipate insightful discussions and analysis surrounding these findings.
Attendance Information
For those intending to engage with ITM at ESMO, the oral presentation is scheduled for Saturday for a substantial window of time, allowing ample opportunity for interest among professionals invested in oncology innovations.
Educational Event for Networking and Learning
Beyond the scientific presentations, ITM will also host a dedicated educational event called “Precision Meets Practice: A NETworking Experience.” Moderated by Dr. Angela Lamarca, a recognized NET expert, this networking opportunity will take place the following Sunday evening and is geared towards emerging healthcare professionals across various fields including oncology and nuclear medicine.
Event Objectives
The objective of this event is clear: to foster interdisciplinary collaboration among young professionals while addressing the latest advancements in theranostics. Given the limited space available, those interested in participating are encouraged to register early through a designated email address.
Event Timing and Location
This exciting event is set for Sunday evening. Details including the precise location within Berlin will be communicated with participants upon registration, ensuring a productive and enriching experience.
ITM’s Presence at the Congress
ITM will maintain a strong presence at the ESMO Congress with a booth showcasing their innovative advancements in radiopharmaceutical therapy (RPT). Attendees are invited to visit booth number 2030 to learn more about groundbreaking research and their extensive pipeline.
Understanding the COMPETE Trial
The COMPETE trial (NCT03049189) serves as a pivotal benchmark within GEP-NET research, having evaluated 177Lu-edotreotide (ITM-11), a cutting-edge radiotherapeutic agent. This trial compared the performance of 177Lu-edotreotide against everolimus, a recognized targeted therapy, specifically in patients facing inoperable, progressive Grade 1 or Grade 2 GEP-NETs. Compellingly, the trial met its primary endpoint, showcasing a significant enhancement in progression-free survival (PFS) when using 177Lu-edotreotide.
Future Research Directions
Excitingly, 177Lu-edotreotide is also undergoing investigation in the COMPOSE trial, which aims to gather more insights into its efficacy among patients with aggressive Grade 2 or Grade 3, SSTR-positive GEP-NETs, underscoring ITM’s commitment to advancing cancer treatment.
About ITM Isotope Technologies Munich SE
ITM continues to set the gold standard in radiopharmaceutical treatments and diagnostics, ardently serving the needs of cancer patients worldwide. They prioritize developing and supplying high-quality radioisotopes, driven by a mission to enhance patient outcomes significantly. ITM is actively working on several Phase 3 trials, showcasing their wide-ranging pipeline that combines superior radioisotopes with varied targeting molecules.
Commitment to Excellence
With two decades of expertise, ITM leverages its established global network and industry position to deliver effective, targeted treatments aiming to improve not only survival rates but overall quality of life for patients battling cancer.
Frequently Asked Questions
What is the COMPETE trial?
The COMPETE trial evaluated a new radiotherapeutic agent, 177Lu-edotreotide, against everolimus in treating specific neuroendocrine tumors.
When will ITM present the COMPETE trial data?
ITM will present the data during a session at the ESMO Congress on a Saturday in October.
What is the purpose of ITM's educational event?
The event aims to facilitate discussions and networking among healthcare professionals in oncology and related fields to promote collaboration.
Where will the educational event take place?
The educational event will occur in Berlin, with specific location details shared upon registration.
How can I contact ITM for more information?
For inquiries, you can reach ITM's corporate communications through their designated email or phone number provided in the article.
